Vascular News and Research

RSS

Baylor University researchers awarded grant to research and test new compounds for cancer

The National Institutes of Health has awarded two Baylor University researchers a $1.46 million grant to research and test new compounds that could help fight cancerous tumors.

18 Jun 2010

Medical Simulation announces new agreement with New York's North Shore-LIJ Health System

Medical Simulation Corporation (MSC) proudly announces a new agreement with the North Shore-LIJ Health System, New York's largest health system and recipient of the 2010 National Quality Healthcare Award from the National Quality Forum. The agreement includes the sale of MSC's endovascular simulation system, Simantha®, and licensing of MSC's curriculum and training services to advance North Shore's education and patient safety goals over the next three years.

18 Jun 2010

Alzheimer's disease may damage brain

Alzheimer's disease has long been studied primarily as a disease of neurons. But researchers have now shown how the disease may be damaging the brain by choking off blood flow. In experiments published June 10 in Neuron, scientists at Rockefeller University reveal that amyloid-β, which builds up around brain cells in Alzheimer's patients, interacts with a common blood clotting agent to increase clotting in the arteries that feed the brain.

17 Jun 2010

New perspectives in type 2 diabetes, cardiovascular risk, and treatment goals

An article published in the May 2010 issue of Postgraduate Medicine highlights the seriousness of cardiovascular disease (CVD) in patients with type 2 diabetes. Cardiovascular disease is the cause of death in > 65% of patients with diabetes, and when complicated by the presence of obesity, the lifetime risk of developing CVD increases to 90%. The inherent problem is that many of the antihyperglycemic medications used to combat high glycated hemoglobin are associated with weight gain and/or hypoglycemia, which negatively affect CVD.

16 Jun 2010

OXiGENE completes enrollment in ZYBRESTAT Phase 2 FALCON trial for NSCLC

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it has completed its targeted enrollment of 60 patients in the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT™ in patients with non-squamous non-small cell lung cancer (NSCLC).

16 Jun 2010

InfraReDx to demonstrate LipiScan coronary imaging system during CCC Symposium

InfraReDx, Inc., an innovative medical device company focused on developing novel diagnostic imaging technologies to accurately identify and characterize diseased tissues, today announced that its LipiScan Coronary Imaging System will be featured at the 13th Annual Live Symposium of Complex Coronary & Vascular Cases being held at The Mount Sinai Medical Center of New York, from June 16-19, 2010.

16 Jun 2010

Normal daily activity best for patients with low-back pain: Study

For much of the 20th century, "rest"— which generally meant a few days to a week in bed — was the standard prescription for acute low-back pain. In recent decades, however, doctors started counseling patients to stay as active as they could.

16 Jun 2010

Central Washington Hospital improves patient experience with Toshiba' Vantage Titan MR system

In today's demanding health care environment, many community hospitals require imaging equipment that provides a variety of advanced diagnostic exams with features that improve patient cooperation. To offer a variety of high-quality, comfortable MR exams to its patients, Central Washington Hospital in Wenatchee, Wash., selected Toshiba America Medical Systems' Vantage TitanTM MR system.

15 Jun 2010

Pieris commences PRS-050 anti-VEGF Anticalin Phase I clinical trial for cancer

Pieris AG announced today the initiation of a Phase I clinical trial in cancer patients for its lead program, PRS-050, an anti-VEGF Anticalin. The trial is an open-label, dose-escalating evaluation of the compound's safety and tolerability in patients with solid tumors. Conducted at three sites in Germany, the trial is underway and patients from the first cohort have been dosed.

15 Jun 2010

MRSA survivors unite across the globe to raise awareness and educate public on prevention

MRSA Survivors Network with MRSA survivors, family members and other victims of healthcare-acquired infections unite across the globe and on World MRSA Day, October 2, 2010 in a grassroots movement to raise awareness and push for more mandated reporting of infections, MRSA screening laws, funds to raise awareness and educate the public on prevention, which will save lives.

15 Jun 2010

ARBs increase risk of cancer: Study

University Hospitals Case Medical Center cardiologists have uncovered new research showing an increased risk of cancer with a group of blood pressure medications known as angiotensin-receptor blockers (ARBs).

14 Jun 2010

National MS Society commits over $2.4M to support 7 CCSVI research projects

Over $2.4 million has been committed by the National MS Society (USA) and the MS Society of Canada to support 7 new research projects focusing on the role of CCSVI in MS.

14 Jun 2010

Discarded livers have potential to be reengineered into usable replacement organs: Researchers

A team led by researchers from the Center for Engineering in Medicine at Massachusetts General Hospital has developed a technique that someday may allow growth of transplantable replacement livers. In their report that will be published in Nature Medicine and is receiving early online release, the investigators describe using the structural tissue of rat livers as scaffolding for the growth of tissue regenerated from liver cells introduced through a novel reseeding process.

14 Jun 2010

Asymptomatic perioperative arrhythmias can lead to sudden cardiac death after surgery: Researchers

Vascular surgery may be accompanied by cardiovascular complications, like ventricular tachyarrhythmia. Though, these arrhythmias initially might be asymptomatic, they can lead to increased risk for late sudden cardiac death after surgery. Researchers from the Netherlands believe that cardiac high-risk patients with new-onset perioperative VT might benefit from preemptive cardioverter defibrillator implantation in addition to optimal focused medical therapy.

14 Jun 2010

Boston Scientific announces event schedule at 17th Cardiostim World Congress

Boston Scientific Corporation today announced the schedule of the Company's key events and sponsored research at the 17th Cardiostim World Congress, June 16 – 19 in Nice, France.

11 Jun 2010

Phase 2b RESTORE-CLI clinical trial in patients with CLI reaches statistical significance

Richard J. Powell, M.D., section chief of vascular surgery at the Dartmouth-Hitchcock Medical Center in Lebanon, NH and a principal investigator of the U.S. Phase 2b RESTORE-CLI clinical trial sponsored by Aastrom Biosciences, will present the full results from the interim analysis at today's session of the annual meeting of the Society for Vascular Surgery.

11 Jun 2010

Gore introduces new internet cloud-based 3-D modeling system and case planning aid

W. L. Gore & Associates (Gore) today announced the launch of a new internet cloud-based 3-D advanced visualization and decision support system to aid physicians in case planning at the Society for Vascular Surgery's 2010 Vascular Annual Meeting being held in Boston, Massachusetts.

11 Jun 2010

UK scientists discover cancer-blocking activity in Down's syndrome chromosome

Cancer Research UK scientists have discovered cancer-blocking activity for genes carried on chromosome 21 - an extra copy of which is carried by people with Down's syndrome, reveals research published in Nature.

11 Jun 2010

New study data on distal aortic perfusion for thoracoabdominal aortic aneurysm repair

The vascular surgeons at Massachusetts General Hospital (MGH) in Boston have traditionally repaired thoracoabdominal aortic aneurysms (TAA) with a clamp and sew (CS) technique that includes neuro-protective adjuncts like epidural cooling and aggressive intercostal reconstruction (IC) to prevent spinal cord ischemia.

11 Jun 2010

Widely used cancer drug bevacizumab can lead to proteinuria, kidney damage: Study

The widely used cancer drug bevacizumab may cause severe loss of protein from the kidney into the urine that can lead to significant kidney damage and can compromise the efficacy of cancer treatment, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology. The results suggest that physicians should monitor patients' kidney health when prescribing this angiogenesis inhibitor.

11 Jun 2010

Vascular News and Research

Baylor University researchers awarded grant to research and test new compounds for cancer

Medical Simulation announces new agreement with New York's North Shore-LIJ Health System

Alzheimer's disease may damage brain

New perspectives in type 2 diabetes, cardiovascular risk, and treatment goals

OXiGENE completes enrollment in ZYBRESTAT Phase 2 FALCON trial for NSCLC

InfraReDx to demonstrate LipiScan coronary imaging system during CCC Symposium

Normal daily activity best for patients with low-back pain: Study

Central Washington Hospital improves patient experience with Toshiba' Vantage Titan MR system

Pieris commences PRS-050 anti-VEGF Anticalin Phase I clinical trial for cancer

MRSA survivors unite across the globe to raise awareness and educate public on prevention

ARBs increase risk of cancer: Study

National MS Society commits over $2.4M to support 7 CCSVI research projects

Discarded livers have potential to be reengineered into usable replacement organs: Researchers

Asymptomatic perioperative arrhythmias can lead to sudden cardiac death after surgery: Researchers

Boston Scientific announces event schedule at 17th Cardiostim World Congress

Phase 2b RESTORE-CLI clinical trial in patients with CLI reaches statistical significance

Gore introduces new internet cloud-based 3-D modeling system and case planning aid

UK scientists discover cancer-blocking activity in Down's syndrome chromosome

New study data on distal aortic perfusion for thoracoabdominal aortic aneurysm repair

Widely used cancer drug bevacizumab can lead to proteinuria, kidney damage: Study

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News